BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Herring B, Jang S, Whitt J, Goliwas K, Aburjania Z, Dudeja V, Ren B, Berry J, Bibb J, Frost A, Chen H, Rose JB, Jaskula-Sztul R. Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates. Front Endocrinol (Lausanne) 2021;12:710009. [PMID: 35002949 DOI: 10.3389/fendo.2021.710009] [Reference Citation Analysis]
2 Fehrenbach U, Xin S, Hartenstein A, Auer TA, Dräger F, Froböse K, Jann H, Mogl M, Amthauer H, Geisel D, Denecke T, Wiedenmann B, Penzkofer T. Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers (Basel) 2021;13:2726. [PMID: 34072865 DOI: 10.3390/cancers13112726] [Reference Citation Analysis]
3 Somasundaram NP, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Dissanayake HA, Yogendranathan N, Gamage KKK, de Silva NL, Sumanatilleke M, Katulanda P, Grossman AB. The Impact of SARS-Cov-2 Virus Infection on the Endocrine System. J Endocr Soc. 2020;4:bvaa082. [PMID: 32728654 DOI: 10.1210/jendso/bvaa082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
4 Becker A, Schalin-Jäntti C, Itkonen O. Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms. J Endocr Soc 2021;5:bvab106. [PMID: 34195530 DOI: 10.1210/jendso/bvab106] [Reference Citation Analysis]
5 Liberini V, De Santi B, Rampado O, Gallio E, Dionisi B, Ceci F, Polverari G, Thuillier P, Molinari F, Deandreis D. Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor. EJNMMI Phys 2021;8:21. [PMID: 33638729 DOI: 10.1186/s40658-021-00367-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Detjen KM, Otto R, Giesecke Y, Geisler L, Riemer P, Jann H, Grötzinger C, Sers C, Pascher A, Lüdde T, Leser U, Wiedenmann B, Sigal M, Tacke F, Roderburg C, Hammerich L. Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2021;13:4463. [PMID: 34503273 DOI: 10.3390/cancers13174463] [Reference Citation Analysis]
7 Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021;22:73. [PMID: 34185197 DOI: 10.1007/s11864-021-00863-y] [Reference Citation Analysis]
8 Pirasteh A, Lovrec P, Pedrosa I. Imaging and its Impact on Defining the Oligometastatic State. Semin Radiat Oncol 2021;31:186-99. [PMID: 34090645 DOI: 10.1016/j.semradonc.2021.03.006] [Reference Citation Analysis]
9 Heijkoop B, Perera M, Kelly BD, Bolton D. Metastatic neuroendocrine tumour presenting as a testicular mass. BMJ Case Rep 2021;14:e240042. [PMID: 33541948 DOI: 10.1136/bcr-2020-240042] [Reference Citation Analysis]
10 Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R. Chemotherapy in NEN: still has a role? Rev Endocr Metab Disord 2021;22:595-614. [PMID: 33843007 DOI: 10.1007/s11154-021-09638-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Reference Citation Analysis]
12 Saponjski J, Macut D, Sobic-Saranovic D, Ognjanovic S, Bozic Antic I, Pavlovic D, Artiko V. Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix. World J Clin Cases 2020; 8(17): 3697-3707 [PMID: 32953846 DOI: 10.12998/wjcc.v8.i17.3697] [Reference Citation Analysis]
13 Chen JX, Lin Y, Meng YL, Zhao AX, Huang XJ, Liang R, Li YQ, Liu ZH. Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram. Biomed Res Int 2021;2021:9126351. [PMID: 33575356 DOI: 10.1155/2021/9126351] [Reference Citation Analysis]
14 Khan MS, Stamp E, Sammon C, Brabander T, de Herder WW, Pavel ME. Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. EJC Suppl 2021;16:5-13. [PMID: 34912478 DOI: 10.1016/j.ejcsup.2021.06.002] [Reference Citation Analysis]
15 Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22:1179. [PMID: 34475969 DOI: 10.3892/etm.2021.10613] [Reference Citation Analysis]
16 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
17 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021; 13(3): 231-255 [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lima Ferreira J, Marques B, Menke-van der Houven van Oordt CW, de Herder WW, Brabander T, Hofland J. Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features. Endocrinol Diabetes Metab Case Rep 2021;2021:EDM200172. [PMID: 33982661 DOI: 10.1530/EDM-20-0172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Soldevilla B, López-López A, Lens-Pardo A, Carretero-Puche C, Lopez-Gonzalvez A, La Salvia A, Gil-Calderon B, Riesco-Martinez MC, Espinosa-Olarte P, Sarmentero J, Rubio-Cuesta B, Rincón R, Barbas C, Garcia-Carbonero R. Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance. Cancers (Basel) 2021;13:2634. [PMID: 34072010 DOI: 10.3390/cancers13112634] [Reference Citation Analysis]
20 Shi X, Li Q, Zhang L, Hanyu M, Xie L, Hu K, Nagatsu K, Zhang C, Wu Z, Wang F, Zhang MR, Yang K, Zhu R. 211At-Labeled Polymer Nanoparticles for Targeted Radionuclide Therapy of Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR)-Overexpressed Cancer. Bioconjug Chem 2021. [PMID: 34260853 DOI: 10.1021/acs.bioconjchem.1c00263] [Reference Citation Analysis]
21 Feola T, Puliani G, Sesti F, Modica R, Biffoni M, Di Gioia C, Carletti R, Anastasi E, Di Vito V, Centello R, Lenzi A, Isidori AM, Faggiano A, Giannetta E. Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature. Front Endocrinol (Lausanne) 2020;11:397. [PMID: 32765421 DOI: 10.3389/fendo.2020.00397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Półtorak-Szymczak G, Budlewski T, Furmanek MI, Wierzba W, Sklinda K, Walecki J, Mruk B. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods. Front Oncol 2021;11:670233. [PMID: 34211845 DOI: 10.3389/fonc.2021.670233] [Reference Citation Analysis]
23 Zhou S, Jiang S, Chen W, Yin H, Dong L, Zhao H, Han S, He X. Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram. Front Oncol 2021;11:654439. [PMID: 34350109 DOI: 10.3389/fonc.2021.654439] [Reference Citation Analysis]
24 Klomp MJ, Dalm SU, de Jong M, Feelders RA, Hofland J, Hofland LJ. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Rev Endocr Metab Disord 2021;22:495-510. [PMID: 33085037 DOI: 10.1007/s11154-020-09607-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 2021;13:17588359211042689. [PMID: 34484432 DOI: 10.1177/17588359211042689] [Reference Citation Analysis]
26 Shah RG, Merlin MA, Adant S, Zine-Eddine F, Beauregard JM, Shah GM. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers (Basel) 2021;13:E232. [PMID: 33435224 DOI: 10.3390/cancers13020232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Chevalier B, Dupuis H, Jannin A, Lemaitre M, Do Cao C, Cardot-Bauters C, Espiard S, Vantyghem MC. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Front Endocrinol (Lausanne) 2021;12:678869. [PMID: 34025587 DOI: 10.3389/fendo.2021.678869] [Reference Citation Analysis]
28 Zandee WT, Brabander T, Blažević A, Minczeles NS, Feelders RA, de Herder WW, Hofland J. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. J Clin Endocrinol Metab 2021;106:e3665-72. [PMID: 33942075 DOI: 10.1210/clinem/dgab289] [Reference Citation Analysis]
29 Lithgow K, Venkataraman H, Hughes S, Shah H, Kemp-Blake J, Vickrage S, Smith S, Humphries S, Elshafie M, Taniere P, Diaz-Cano S, Dasari BVM, Almond M, Ford S, Ayuk J, Shetty S, Shah T, Geh I. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort. Sci Rep 2021;11:17947. [PMID: 34504148 DOI: 10.1038/s41598-021-97247-x] [Reference Citation Analysis]
30 Casey RT, Valk GD, Schalin-Jäntti C, Grossman AB, Thakker RV. ENDOCRINOLOGY IN THE TIME OF COVID-19: Clinical management of neuroendocrine neoplasms (NENs). Eur J Endocrinol 2020;183:G79-88. [PMID: 32554825 DOI: 10.1530/EJE-20-0424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]